Imodium and Microangiopathy - a phase IV clinical study of FDA data

Summary:

Microangiopathy is reported as a side effect among people who take Imodium (loperamide hydrochloride), especially for people who are female, 60+ old, also take Cephalexin, and have Osteoporosis.

The phase IV clinical study analyzes which people have Microangiopathy when taking Imodium. It is created by eHealthMe based on reports of 44,210 people who have side effects when taking Imodium from the FDA, and is updated regularly.

What is Imodium?

Imodium has active ingredients of loperamide hydrochloride. It is often used in diarrhea. eHealthMe is studying from 45,092 Imodium users. Check the latest studies of Imodium.

What is Microangiopathy?

Microangiopathy (disease of the capillaries (very small blood vessels), in which the capillary walls become so thick and weak that they bleed, leak protein) is found to be associated with 236 drugs and 331 conditions by eHealthMe. Check the latest studies of Microangiopathy.

On Jul, 14, 2026

44,210 people reported to have side effects when taking Imodium.
Among them, 12 people (0.03%) have Microangiopathy.

Among these 12 people:

What is the gender of people who have Microangiopathy when taking Imodium? *

female: 75 %
male: 25 %

What is the age of people who have Microangiopathy when taking Imodium? *

What are other drugs people take besides Imodium? *

What are other side effects people have besides Microangiopathy? *

Joint Swelling: 11 people, 91.67%
Pain: 11 people, 91.67%
Fainting (loss of consciousness and postural tone): 11 people, 91.67%
Fall: 11 people, 91.67%
Gastritis (inflammation of stomach): 11 people, 91.67%
Urinary Tract Infection: 11 people, 91.67%
Stress And Anxiety: 11 people, 91.67%
Back Pain: 11 people, 91.67%
Osteopenia (a condition where bone mineral density is lower than normal): 11 people, 91.67%
Intertrigo (inflammation (rash) of the body folds (adjacent areas of skin)): 10 people, 83.33%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 10 people, 83.33%
Speech Impairment (Adult) (inability to speak (adult)): 1 person, 8.33%
Gastroesophageal Cancer: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Imodium and have Microangiopathy?

- Check whether Microangiopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imodium:

Imodium (45,092 reports)

Microangiopathy treatments and more:

Microangiopathy (1,304 reports)

Browse all side effects of Imodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Microangiopathy:

Microangiopathy (236 drugs)

Browse all the conditions that are associated with Microangiopathy:

Microangiopathy (331 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on loperamide hydrochloride (the active ingredients of Imodium) and Imodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.